Henry Schein Presents a Comprehensive Lineup of Solutions at the 2024 Chicago Dental Society Midwinter Meeting
Company’s Holistic Approach to Elevating the Customer Experience on Display MELVILLE, N.Y.–(BUSINESS WIRE)–Henry Schein, Inc. (Nasdaq: HSIC) today... Read more.
CDW to Present at the Raymond James 45th Annual Institutional Investors Conference
VERNON HILLS, Ill.–(BUSINESS WIRE)–CDW Corporation (Nasdaq: CDW), a leading multi-brand provider of information technology solutions to business, government,... Read more.
PropTech Innovator VeriFast: Data Analytics Essential to Colorblind Mortgage Process
Allegations of prejudice against top lenders highlight inaccuracy and bias of credit report algorithms, creating “redlining 2.0.” NEW YORK–(BUSINESS WIRE)–VeriFast,... Read more.
Bestway Europe Unlocks New Market Potential and Accelerates Business Growth with BigCommerce
Taking a composable approach with a headless front-end, Bestway Europe maximizes the flexibility and customization to create compelling customer experiences, simplify... Read more.
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU NEW YORK–(BUSINESS... Read more.
Global Maritime Analytics Market Analysis Report 2024-2028: The Rising Popularity of Marine Tourism – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Maritime Analytics Market: Analysis By Application, By End User, By Region Size, Trends and Forecast to 2028”... Read more.
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
Application based on results from the TROPION-Lung01 Phase III trial If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed... Read more.
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting WILMINGTON, Del.–(BUSINESS WIRE)–Positive... Read more.
Pulsate Raises $7.75M in Series A Funding Backed By TruStage Ventures and Curql
DUBLIN–(BUSINESS WIRE)–In response to continued demand for better consumer engagement tools for the digital channel, Pulsate, provider of mobile-first... Read more.
Pulsate Raises $7.75M in Series A Funding Backed By TruStage Ventures and Curql
DUBLIN–(BUSINESS WIRE)–In response to continued demand for better consumer engagement tools for the digital channel, Pulsate, provider of mobile-first... Read more.